Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Pembrolizumab and Hypofractionated Radiation Therapy for Mucosal Melanoma
NCT04318717Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- May 2020
- Primary completion
- Jul 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in mucosal melanoma (MM), sponsored by Washington University School of Medicine. Started May 2020; status: recruiting.
02
Drugs
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT04318717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318717.